The GNRH1 Knockout UM-UC-3 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the UM-UC-3 human urothelial carcinoma cell line. This product features disruption of the GNRH1 gene, which encodes the gonadotropin-releasing hormone (GnRH) neuropeptide, through targeted CRISPR/Cas9-mediated gene editing. The resulting polyclonal pool contains a heterogeneous mixture of cells carrying diverse loss-of-function mutations, enabling robust assessment of GNRH1-dependent phenotypes without clonal selection bias. These cells provide a versatile loss-of-function model for investigating GnRH signaling in a bladder cancer context.
The UM-UC-3 cell line was originally established from a male patient with transitional cell carcinoma of the bladder and serves as a widely used model for high-grade invasive urothelial carcinoma. These cells exhibit characteristic features of aggressive bladder cancer, including anchorage-independent growth and invasive potential, making them particularly suitable for studying tumor progression mechanisms. The UM-UC-3 background retains key signaling pathways relevant to urothelial malignancy, providing a physiologically appropriate platform for dissecting the contributions of GNRH1 to cancer cell behavior.
GNRH1 encodes the hypothalamic decapeptide GnRH, which classically governs pituitary gonadotropin secretion via its cognate receptor GNRHR. Beyond its neuroendocrine role, GnRH acts as an autocrine/paracrine factor in multiple cancer types, where it modulates cell proliferation, migration, and invasion. GnRH binding to GNRHR activates G??q/11 proteins, stimulating phospholipase C?? (PLC??) to generate inositol trisphosphate (IP3) and diacylglycerol (DAG), leading to calcium mobilization and protein kinase C (PKC) activation. Downstream, this triggers the mitogen-activated protein kinase (MAPK) cascade, including RAF, MEK, and ERK1/2, as well as the PI3K-AKT pathway. The GNRH1 gene is regulated by upstream factors such as kisspeptin (KISS1), neurokinin B (TAC3), and steroid hormones, and its expression ultimately influences transcription factors like AP-1 through ERK-mediated signaling.
In UM-UC-3 bladder cancer cells, GNRH1 knockout eliminates autocrine/paracrine GnRH signaling, thereby disrupting the MAPK and PI3K-AKT cascades that promote tumor cell proliferation and invasion. Studies in urothelial carcinoma have implicated GnRH in sustaining oncogenic drive, and this knockout model permits systematic dissection of GNRH1-dependent mechanisms in a relevant cellular environment. By uncoupling the GnRH?CGNRHR axis, researchers can interrogate how loss of this neuropeptide hormone affects downstream effectors such as ERK phosphorylation and AP-1 transcriptional activity, clarifying its contribution to bladder cancer pathophysiology.
These polyclonal knockout cells are ideally suited for applications including the elucidation of GnRH??s role in bladder cancer cell biology, investigation of neuropeptide signaling in cancer, and screening of pharmacological agents targeting the GnRH pathway. Supporting experimental approaches encompass Western blotting, RT-qPCR, migration and invasion assays, proliferation analyses (MTT/BrdU), phospho-ERK quantification, and ligand-binding studies. By providing a tool for dissecting GNRH1 function, this product accelerates discovery in reproductive neuroendocrinology and cancer research. For additional information or technical support, please contact Ascent Research.
